8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today
PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Baidu Reports Q2 2026 Results: Full Earnings Call Transcript
Baidu (NASDAQ:BIDU) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Is Baidu Inc. (BIDU) a Buy as Wall Street Analysts Look Optimistic?
While Baidu Inc. (BIDU) holds a Buy-equivalent average brokerage recommendation (ABR) of 1.75 from 21 analysts, the Zacks Rank system assigns it a Strong Sell rating due to a 19.3% decline in consensus earnings estimates over the past month. The article highlights the disconnect between potentially biased brokerage recommendations and the more reliable Zacks Rank, which is driven by earnings estimate revisions and has historically outperformed the S&P 500.